Abstract
Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4%) than the PES group (84.3%, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.
| Original language | English |
|---|---|
| Pages (from-to) | 302-306 |
| Number of pages | 5 |
| Journal | International Journal of Cardiology |
| Volume | 152 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2011 Nov 3 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
}
Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents : A propensity matched study: Clinical evidence of late catch-up? / Ko, Young Guk; Kim, Jung Sun; Choi, Donghoon; Hong, Myeongki; Min, Pil Ki; Yoon, Young Won; Hong, Bum Kee; Lee, Byoung Kwon; Kwon, Hyuck Moon; Kim, Byeong Keuk; Oh, Sung Jin; Jeon, Dong Wun; Yang, Joo Young; Jang, Yangsoo.
In: International Journal of Cardiology, Vol. 152, No. 3, 03.11.2011, p. 302-306.Research output: Contribution to journal › Article
TY - JOUR
T1 - Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents
T2 - A propensity matched study: Clinical evidence of late catch-up?
AU - Ko, Young Guk
AU - Kim, Jung Sun
AU - Choi, Donghoon
AU - Hong, Myeongki
AU - Min, Pil Ki
AU - Yoon, Young Won
AU - Hong, Bum Kee
AU - Lee, Byoung Kwon
AU - Kwon, Hyuck Moon
AU - Kim, Byeong Keuk
AU - Oh, Sung Jin
AU - Jeon, Dong Wun
AU - Yang, Joo Young
AU - Jang, Yangsoo
PY - 2011/11/3
Y1 - 2011/11/3
N2 - Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4%) than the PES group (84.3%, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.
AB - Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4%) than the PES group (84.3%, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.
UR - http://www.scopus.com/inward/record.url?scp=80055048980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055048980&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2010.07.023
DO - 10.1016/j.ijcard.2010.07.023
M3 - Article
C2 - 20708806
AN - SCOPUS:80055048980
VL - 152
SP - 302
EP - 306
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 3
ER -